Phase II study of interferon-alpha (IFN), Gleevec or Iressa patients with metastatic renal cell carcinoma.

被引：0
|
作者：
Amato, R [1 ]
Kareidy, M [1 ]
Marsh, L [1 ]
Truong, L [1 ]
Shen, S [1 ]
机构：
[1] Methodist Hosp, Res Inst, Houston, TX 77030 USA
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9030S / 9030S
页数：1
相关论文
共 50 条
  • [1] Interferon-α in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma:: a phase II trial
    Amato, Robert J.
    Jac, Jaroslaw
    Hernandez-McClain, Joan
    [J]. ANTI-CANCER DRUGS, 2008, 19 (05) : 527 - 533
  • [2] Phase II study of interferon and thalidomide in metastatic renal cell carcinoma.
    Tripathi, RR
    Patel, B
    Heilbrun, L
    Hussain, M
    Flaherty, L
    Vaishampayan, UN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 434S - 434S
  • [3] PHASE-II STUDY OF INTERFERON-ALPHA IN METASTATIC RENAL-CELL CARCINOMA - A PROGRESS REPORT
    QUESADA, JR
    SWANSON, DA
    GUTTERMAN, JU
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (08) : 1086 - 1092
  • [4] Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma
    Michael Huie
    Kurt Oettel
    Lynn Van Ummersen
    Kyung Mann Kim
    Yulin Zhang
    Mary Jane Staab
    Dottie Horvath
    Rebecca Marnocha
    Jeff Douglas
    Amy Drezen
    Dona Alberti
    George Wilding
    [J]. Investigational New Drugs, 2006, 24 : 255 - 260
  • [5] Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma
    Huie, M
    Oettel, K
    Van Ummersen, L
    Kim, KM
    Zhang, YL
    Staab, MJ
    Horvath, D
    Marnocha, R
    Douglas, J
    Drezen, A
    Alberti, D
    Wilding, G
    [J]. INVESTIGATIONAL NEW DRUGS, 2006, 24 (03) : 255 - 260
  • [6] A phase II study of imatinib mesylate (IM) and interferon-alpha (IFNA) in metastatic renal cell carcinoma (RCC).
    Polite, BN
    Desai, AA
    Peterson, AC
    Manchen, B
    Stadler, WM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 425S - 425S
  • [7] Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma
    Vuky, J
    Isacson, C
    Fotoohi, M
    dela Cruz, J
    Otero, H
    Picozzi, V
    Malpass, T
    Aboulafia, D
    Jacobs, A
    [J]. INVESTIGATIONAL NEW DRUGS, 2006, 24 (01) : 85 - 88
  • [8] Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan
    Masatoshi Eto
    Yoshiaki Kawano
    Yoshihiko Hirao
    Koji Mita
    Yoichi Arai
    Taiji Tsukamoto
    Katsuyoshi Hashine
    Akio Matsubara
    Tomoaki Fujioka
    Go Kimura
    Nobuo Shinohara
    Katsunori Tatsugami
    Shiro Hinotsu
    Seiji Naito
    [J]. BMC Cancer, 15
  • [9] Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan
    Eto, Masatoshi
    Kawano, Yoshiaki
    Hirao, Yoshihiko
    Mita, Koji
    Arai, Yoichi
    Tsukamoto, Taiji
    Hashine, Katsuyoshi
    Matsubara, Akio
    Fujioka, Tomoaki
    Kimura, Go
    Shinohara, Nobuo
    Tatsugami, Katsunori
    Hinotsu, Shiro
    Naito, Seiji
    [J]. BMC CANCER, 2015, 15
  • [10] Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma
    Jacqueline Vuky
    Christina Isacson
    Mehran Fotoohi
    Jason dela Cruz
    Henry Otero
    Vincent Picozzi
    Thomas Malpass
    David Aboulafia
    Andrew Jacobs
    [J]. Investigational New Drugs, 2006, 24 : 85 - 88
12345